Manuel Alberto Amaris
Motility Program Director and Clinical Associate Professor
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
About
Manuel Alberto Amaris is the Motility Program Director and Clinical Associate Professor at the University of Florida, USA. His research focuses on areas including gastrointestinal motility, esophageal dysmotility, and the impact of neuroinflammation on gastrointestinal conditions. Recent articles highlight his work on outcomes in lung transplantation and innovative treatment approaches for esophageal motility disorders.
Articles (7)
Background The complexity of gastrointestinal (GI) disorders associated with Parkinson's disease (PD) and the significant interactions between GI medications and the dopaminergic axis necessitates expert management. The integrated care model for disorders of the brain-gut interaction (DBGI) has advantages, however, has not been applied in concurrent DBGI and PD. Objective To test the hypothesis that our Parkinson's Research and Integrated Support Model (PRISM) will reduce symptom severity and improve the quality of life (QOL) in patients with GI symptoms associated with PD. Methods Patients with refractory GI symptoms referred to the PRISM clinic were evaluated and treated by the integrated efforts of movement disorder specialists, neurogastroenterologists, dietitians, occupational therapists, speech-swallow therapists, and neuroscientists. Patients underwent a battery of GI symptoms and QOL questionnaires and personalized actionable biomarkers (motility testing and swallowing studies). Inflammatory markers and stool tests were collected. An individualized standard of care treatment was established based on the specific DBGI diagnosis uncovered during the PRISM evaluation. Results 44 adult PD patients with GI complaints were evaluated. The most common symptoms included constipation (97%), dysphagia (61%), and gastroesophageal reflux (34%). Actionable biomarkers were highly positive revealing esophageal dysmotility (20/21, 95%), slow-transit constipation (40/42, 90%), intestinal methanogen overgrowth (7/8, 87%), gastroparesis (17/20, 85%), oropharyngeal dysphagia (28/44, 63%), and dyssynergic defecation (27/42, 61%). GI symptom severity and QOL significantly improved ( p < 0.05) as measured by all questionnaires. Conclusions More severely affected patients with Parkinson's treated with the Fixel PRISM approach showed significant improvements in GI symptom frequency, severity, and QOL.
Year:
2025
Year:
2024
Year:
2023
Year:
2023
Year:
2023
Year:
2022
Year:
2020
Collaborators (2)
Vinata Vedam-Mai
University of Florida
Michael Okun
Member
Fixel Institute for Neurological Diseases
Make your next move.
Prepare your application
Review drafts before you send them.